Navigation Links
Erlotinib effective and with fewer side-effects after first-line treatment
Date:2/26/2011

The targeted cancer drug erlotinib has comparable efficacy to chemotherapy, and is better tolerated, in hard-to-treat cases where a patient's cancer has progressed quickly after treatment with first-line therapy, the results of a new phase III trial show.

Dr Tudor Ciuleanu from the Institute of Oncology Ion Chiricuta, Cluj-Napoca, Romania, reported this finding from the international TITAN study at the European Multidisciplinary Conference in Thoracic Oncology (EMCTO), 24-26 February 2011, Lugano, Switzerland.

"The TITAN study is the first trial to evaluate whether erlotinib has comparable efficacy to chemotherapy for non-small cell lung cancer patients in general," Dr Ciuleanu said.

The study included only patients whose disease had progressed under first-line chemotherapy. In the clinic, around 30-40% of patients with lung cancer will see no benefit from first-line therapy and their disease will rapidly progress.

"These patients have an extremely poor prognosis and few treatment options. An effective alternative to chemotherapy is therefore very important, since chemo-related side-effects can result in further physical deterioration in patients who are already very sick," Dr Ciuleanu said.

Historically, data have shown that erlotinib was more tolerable than chemotherapy, but many physicians had assumed that erlotinib would not be as effective in this difficult-to-treat patient population compared to chemotherapy.

The open-label study included 424 patients whose lung cancer had progressed rapidly after treatment with first-line chemotherapy. Of these, 203 were treated with erlotinib, and 221 received chemotherapy with either docetaxel or pemetrexed.

No difference in overall survival was seen between the two groups, the researchers reported. Nor was there any significant difference in progression-free survival time.

"TITAN is important because it confirms that erlotinib has comparable efficacy
'/>"/>

Contact: Vanessa Pavinato
media@esmo.org
European Society for Medical Oncology
Source:Eurekalert

Page: 1 2

Related biology news :

1. Oncogene AEG-1 strongly predicts response to erlotinib treatment in EGFR-mutant lung cancer
2. New targeted therapy adds benefit to erlotinib in some patients with advanced lung cancer
3. Erlotinib improves progression-free survival as first-line therapy in advanced lung cancer
4. NYU nursing-dental team receives grant to assess effectiveness of A1C diabetes screening technique
5. Frost & Sullivan Recognizes Cardiocom as a Technology Enabler for Superior Cost-Effective Remote Chronic Care Management
6. Baker Institute conference to examine safety, effectiveness of US offshore drilling industry
7. Early tests find nanoshell therapy effective against brain cancer
8. Immersive data collection, peer networks among key elements of effective watershed councils
9. Frost & Sullivan Recognizes Cardiocom as a Technology Enabler for Superior Cost-Effective Remote Chronic Care Management
10. Marinomeds iota-carrageenan effective against H1N1
11. Estrogen alone is effective for reducing breast cancer risk
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2015)... Huntington Memorial Hospital is the first facility ... miniaturized, wireless monitoring sensor to manage heart failure (HF). ... FDA-approved heart failure monitoring device that has been proven ... to manage heart failure. The CardioMEMS HF ... pulmonary artery (PA) during a non-surgical procedure to directly ...
(Date:4/17/2015)... Increasing adoption in ... to drive biometric systems market in ... According to a recently released TechSci Research ... biometric systems market in Saudi Arabia ... CAGR of over 22% through 2020. The market ...
(Date:4/14/2015)... OXFORD, Conn. , April 14, 2015 ... "Company"), a biometric authentication company focused on the growing ... has been nominated for the 2015 New York Design ... The Design100, New York City Design Awards are ... are based on over 2,500 ratings from the marketplace, ...
Breaking Biology News(10 mins):Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 2Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 3NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 2NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 3
... Amsterdam, 2 November, 2010 - An investigation conducted in the ... Relevance to Humans, Animals and Ecosystems, demonstrates for the first ... is widespread. In the course of the Summer ... was sampled by mothers who had given birth at the ...
... School meal programs play a significant role in ... comprehensive school nutrition services that improve children,s nutritional ... updated joint position paper from the Society for ... the School Nutrition Association (SNA). The updated ...
... NEW YORK, Nov. 2, 2010 The Online Publishers Association ... Effectiveness of the OPA Ad Unit," that found that 90 ... 10 seconds of being on a webpage and users who ... were as emotionally engaged with the advertising as with the ...
Cached Biology News:Exposure of humans to cosmetic UV filters is widespread 2Exposure of humans to cosmetic UV filters is widespread 3Comprehensive nutrition services vital to children's health 2Online Publishers Association Unveils Biometric and Eye Tracking Research to Assess the Effectiveness of New OPA Ad Units 2Online Publishers Association Unveils Biometric and Eye Tracking Research to Assess the Effectiveness of New OPA Ad Units 3
(Date:4/22/2015)... , April 22, 2015  Sangamo BioSciences, Inc. (NASDAQ: ... financial results and accomplishments. For the first ... net loss of $5.3 million, or $0.08 per share, ... $0.12 per share, for the same period in 2014. ... cash equivalents, marketable securities and interest receivable of $226.1 ...
(Date:4/22/2015)... --  MPIRICA Health Inc. , a healthcare quality ... financing from the McQuinn Trust, an early stage, ... employer awareness of MPIRICA.com, delivering easily interpreted, outcomes-based ... hospitals. "As a patient in need ... choosing the hospital and surgeon most likely to ...
(Date:4/22/2015)... 2015 Steep Hill, the industry leader ... it has opened an investment round of $5 ...  The common stock investment round will be offered ... intended to encourage funding of small businesses by ... businesses largely relied on friends and family, venture ...
(Date:4/22/2015)... 22, 2015 Over the ... market witnessed tremendous growth primarily due to ... government support with increased nanotechnology R&D expenditure ... Customization: , http://www.marketsandmarkets.com/requestCustomization.asp?id=65048077 , In ... market is segmented on the basis of ...
Breaking Biology Technology:Sangamo BioSciences Reports First Quarter 2015 Financial Results 2Sangamo BioSciences Reports First Quarter 2015 Financial Results 3Sangamo BioSciences Reports First Quarter 2015 Financial Results 4Sangamo BioSciences Reports First Quarter 2015 Financial Results 5Sangamo BioSciences Reports First Quarter 2015 Financial Results 6Sangamo BioSciences Reports First Quarter 2015 Financial Results 7Sangamo BioSciences Reports First Quarter 2015 Financial Results 8MPIRICA Health Inc. Secures $1.6M to Promote FICO-Like Quality Scores for Surgeries 2Steep Hill Launches $5M Limited Stock Offering 2Steep Hill Launches $5M Limited Stock Offering 3Nanotechnology-based Medical Devices Market to Reach Around $8.5 billion by 2019 - Published by MarketsandMarkets 2Nanotechnology-based Medical Devices Market to Reach Around $8.5 billion by 2019 - Published by MarketsandMarkets 3
... ... Addressing Dynamic Needs of Growing World , ... Wilmington, DE (Vocus) July 9, 2010 -- The world’s population ... than 12 years -- with more than 9 billion people expected on earth before ...
... ... be present at the Process Expo 2010 in Chicago from July 18 ... designing and manufacturing of industrial wastewater treatment systems for the food processing ... technology and that FRC is a major well-known and respected DAF (Dissolved ...
... from microelectronics to power lines because of their ballistic ... those electrons in their tracks? Rice physicist Junichiro ... effect -- the interaction between electrically charged particles and ... nanotubes. While doing so, they came to the ...
Cached Biology Technology:United Nations' World Population Day Calls Attention to Key Global Issues 2United Nations' World Population Day Calls Attention to Key Global Issues 3United Nations' World Population Day Calls Attention to Key Global Issues 4United Nations' World Population Day Calls Attention to Key Global Issues 5FRC Systems International State-of-the-art Industrial Wastewater Treatment Systems 2FRC Systems International State-of-the-art Industrial Wastewater Treatment Systems 3Magnets trump metallics 2
... This CLS number is a new ... Cornings product number. If showing no ... old Sigma-Aldrich number (Z71,405-4) or contact ... diam. 60 mm volume diam. ...
... sets of glass plates, bar clamp, and ... features of these units are:, safety interlock ... reservoirs , upper and lower reservoirs have ... safe disposal of buffer solutions , leveling ...
... stain. Reproducible color staining. ... reversers needed. Stains proteins, ... Linear protein-to-stain color intensity. ... per tray. Packaged as ...
Rabbit polyclonal to Quinaldic Acid ( Abpromise for all tested applications). Antigen: Synthetic peptide Quinaldic Acid conjugated to a protein carrier....
Biology Products: